Literature DB >> 11496113

Reduced corpus callosum, fornix and hippocampus in PDAPP transgenic mouse model of Alzheimer's disease.

F Gonzalez-Lima1, J D Berndt, J E Valla, D Games, E M Reiman.   

Abstract

Persons with Alzheimer's disease (AD) have progressive reductions in the relative sizes of the corpus callosum and hippocampus. Homozygotic PDAPP transgenic mice over-expressing a mutant form of the human amyloid precursor protein have more pronounced reductions in these regions, which are apparent prior to the deposition of amyloid plaques and do not progress with advancing age. The length of the corpus callosum was reduced by two-thirds, the fornix commissure was negligible, and the hippocampal volume was reduced by one-third, suggesting a massive disconnection between the cerebral hemispheres and the hippocampi in PDAPP mice. These findings, which might account for the early, nonprogressive behavioral abnormalities observed in these animals, have implications for the study of AD.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11496113     DOI: 10.1097/00001756-200108080-00018

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  19 in total

1.  Increased regional cerebral glucose uptake in an APP/PS1 model of Alzheimer's disease.

Authors:  Géraldine Poisnel; Anne-Sophie Hérard; Nadine El Tannir El Tayara; Emmanuel Bourrin; Andreas Volk; Frank Kober; Benoit Delatour; Thierry Delzescaux; Thomas Debeir; Thomas Rooney; Jésus Benavides; Philippe Hantraye; Marc Dhenain
Journal:  Neurobiol Aging       Date:  2011-11-12       Impact factor: 4.673

Review 2.  APP transgenic mice for modelling behavioural and psychological symptoms of dementia (BPSD).

Authors:  R Lalonde; K Fukuchi; C Strazielle
Journal:  Neurosci Biobehav Rev       Date:  2012-02-21       Impact factor: 8.989

3.  Age- and transgene-related changes in regional cerebral metabolism in PSAPP mice.

Authors:  Jon Valla; Lonnie Schneider; Eric M Reiman
Journal:  Brain Res       Date:  2006-08-30       Impact factor: 3.252

4.  Magnetic Resonance Imaging for Drug Development.

Authors:  Jeong Kon Kim
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  Regional cerebral glucose uptake in the 3xTG model of Alzheimer's disease highlights common regional vulnerability across AD mouse models.

Authors:  Rachel M Nicholson; Yael Kusne; Lee A Nowak; Frank M LaFerla; Eric M Reiman; Jon Valla
Journal:  Brain Res       Date:  2010-08-06       Impact factor: 3.252

6.  A role for noncanonical microRNAs in the mammalian brain revealed by phenotypic differences in Dgcr8 versus Dicer1 knockouts and small RNA sequencing.

Authors:  Joshua E Babiarz; Ruby Hsu; Collin Melton; Molly Thomas; Erik M Ullian; Robert Blelloch
Journal:  RNA       Date:  2011-06-28       Impact factor: 4.942

7.  Targeting mitochondrial bioenergetics for Alzheimer's prevention and treatment.

Authors:  Jia Yao; Roberta Diaz Brinton
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

8.  Automated detection of amyloid-β-related cortical and subcortical signal changes in a transgenic model of Alzheimer's disease using high-field MRI.

Authors:  Stefan J Teipel; Evangelia Kaza; Stefan Hadlich; Alexandra Bauer; Thomas Brüning; Anne-Sophie Plath; Markus Krohn; Katja Scheffler; Lary C Walker; Martin Lotze; Jens Pahnke
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

9.  In vivo imaging biomarkers in mouse models of Alzheimer's disease: are we lost in translation or breaking through?

Authors:  Benoît Delatour; Stéphane Epelbaum; Alexandra Petiet; Marc Dhenain
Journal:  Int J Alzheimers Dis       Date:  2010-09-30

10.  FDG autoradiography reveals developmental and pathological effects of mutant amyloid in PDAPP transgenic mice.

Authors:  Jon Valla; Francisco Gonzalez-Lima; Eric M Reiman
Journal:  Int J Dev Neurosci       Date:  2008-02-15       Impact factor: 2.457

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.